Press Releases

May 13, 2024
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 10, 2024
Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024
May 3, 2024
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 12, 2024
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
April 2, 2024
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 28, 2024
Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering
March 26, 2024
Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients
Displaying 1 - 10 of 18